TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Nanobiotix ( (NBTX) ) has shared an announcement.
On September 17, 2025, Nanobiotix announced new results from a Phase 1 study evaluating JNJ-1900 (NBTXR3) in combination with immune checkpoint inhibitors for patients with primary cutaneous melanoma resistant to anti-PD-1. The study showed a favorable safety profile and early efficacy signals, with a 47.4% objective response rate and a 78.9% disease control rate. The findings suggest potential for further investigation in randomized clinical trials, potentially offering new treatment options for patients with advanced melanoma.
The most recent analyst rating on (NBTX) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.
Spark’s Take on NBTX Stock
According to Spark, TipRanks’ AI Analyst, NBTX is a Neutral.
Nanobiotix’s stock score is primarily impacted by significant financial instability, marked by declining revenues and negative profitability. However, the stock’s strong technical momentum provides a counterbalance, suggesting potential short-term interest despite the company’s broader financial challenges. Valuation concerns persist due to the negative P/E ratio, reflecting non-profitability.
To see Spark’s full report on NBTX stock, click here.
More about Nanobiotix
Nanobiotix is a late-stage clinical biotechnology company based in Paris, France, with a focus on pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases. The company is listed on Euronext Paris and the Nasdaq Global Select Market, and it holds over 25 patents related to oncology, bioavailability, biodistribution, and central nervous system disorders.
Average Trading Volume: 9,528
Technical Sentiment Signal: Buy
Current Market Cap: $448.4M
See more data about NBTX stock on TipRanks’ Stock Analysis page.